Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the cardiovascular outcomes of elecoglipron compared with a placebo in adults with heart failure with preserved ejection fraction HFpEF or mildly reduced ejection fraction HFmrEF. This Phase III, randomized, double-blind, placebo-controlled study includes participants regardless of type 2 diabetes status who are also taking dapagliflozin along with other standard care treatments. Participants are randomly assigned to receive either elecoglipron tablets once daily or matching placebo tablets once daily. The study is conducted across multiple centers and follows a parallel-group design. The treatment period may last up to 42 months, during which the effects of elecoglipron on cardiovascular events and patient outcomes are assessed. Throughout the study, participants undergo regular evaluations to monitor their heart failure status, including assessments of cardiovascular death risk, hospitalization for heart failure, and urgent heart failure visits. Patient-reported outcomes are collected using questionnaires at baseline and at 52 weeks. Safety and efficacy are closely monitored over the extended treatment period to determine the impact of elecoglipron compared to placebo.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenous thrombolysis IVT in adults who have had an acute ischemic stroke AIS and recently taken direct oral anticoagulants DOACs within the last 48 hours. This international, multicenter, randomized study aims to determine whether IVT combined with standard medical care leads to better outcomes at 90 days compared to standard care alone. The trial is designed as a phase 4 superiority study enrolling 906 participants at several high-volume stroke centers worldwide. Participants will be randomly assigned to one of two groups one group will receive intravenous thrombolysis using Tenecteplase or Alteplase along with the best standard medical treatment, while the other group will receive only the standard of care as per local and international guidelines. Treatment must begin within specific time windows based on stroke onset or MRI findings. The study follows current guidelines from major stroke organizations, ensuring participants receive appropriate care. During the study, participants will be monitored and assessed using the Modified Rankin Scale at 90 days to evaluate functional outcomes. Additional measures include stroke severity changes assessed by the NIH Stroke Scale within 24 hours, and quality of life questionnaires at 90 days. The study includes careful safety monitoring and long-term follow-up to fully assess treatment effects and participant well-being throughout and after the 90-day period.